Low-dose finasteride in benign prostatic hyperplasia: a comprehensive narrative review of efficacy, safety, and preventative potential

Introduction

Benign prostatic hyperplasia (BPH) is a highly prevalent, progressive condition in aging men, characterized by nonmalignant enlargement of the prostate gland and often associated with bothersome lower urinary tract symptoms (LUTS) (1,2). The pathophysiology of BPH is closely linked to intraprostatic dihydrotestosterone (DHT), a potent androgen generated by the type II 5-α-reductase enzyme (3). Inhibitors of this enzyme, such as finasteride, reduce DHT concentrations, leading to prostate volume reduction and symptom improvement (4,5).

The 5 mg formulation of finasteride has been extensively studied, with pivotal trials such as PLESS and MTOPS demonstrating reductions in prostate volume, LUTS progression, risk of acute urinary retention (AUR), and need for surgery (4,6,7). However, the 1 mg dose, approved for androgenic alopecia, also exerts measurable suppression of serum and intraprostatic DHT (8-10), raising the possibility of BPH-modifying effects at lower dosing.

Given that finasteride 1 mg is widely prescribed in younger populations for alopecia (8,11), its long-term influence on prostate growth and urinary outcomes represents a clinically relevant and underexplored question (12). This review evaluates evidence related to finasteride 1 mg and prostate biology, including surrogate markers, safety considerations, and its hypothesis-generating role in early or stepwise approaches to BPH management. We present this article in accordance with the Narrative Review reporting checklist (available at https://tau.amegroups.com/article/view/10.21037/tau-2025-aw-841/rc).

Methods

A structured literature review was conducted using PubMed, EMBASE, and the Cochrane Library from January 1990 through January 2026. The detailed search strategy is summarized in Table 1. Search terms included combinations of “finasteride 1 mg”, “benign prostatic hyperplasia”, “prostate-specific antigen”, “dihydrotestosterone”, “prostate volume”, “lower urinary tract symptoms”, “urinary retention”, “transurethral resection of the prostate”, and “alopecia” (3,8-10,12,13).

The review prioritized evidence evaluating finasteride 1 mg with prostate-relevant biologic or surrogate endpoints, including serum prostate-specific antigen (PSA) suppression and androgen modulation, as well as pharmacodynamic studies describing dose-dependent effects on DHT (8-10). For clinical context, landmark randomized controlled trials (RCTs) evaluating finasteride 5 mg in men with BPH were reviewed to summarize established effects on prostate volume, LUTS, and disease progression (4-7,14).

Inclusion criteria:

• Primary studies evaluating finasteride 1 mg and reporting prostate-relevant biologic or surrogate outcomes (e.g., PSA suppression);
• Pharmacodynamic studies characterizing dose-response relationships of finasteride relevant to prostate biology;
• Seminal RCTs evaluating finasteride 5 mg in men with BPH reporting clinical outcomes (prostate volume, symptom progression, AUR, or need for surgical intervention), included for contextual comparison.

Exclusion criteria:

• Studies reporting only finasteride 5 mg outcomes unrelated to prostate-related endpoints (e.g., studies limited to sexual function or dermatologic outcomes);
• Studies lacking prostate-related clinical, biologic, or surrogate endpoints;
• Case reports or series with fewer than 10 participants;
• Non-English language publications.

Given heterogeneity in study design, populations, dosing strategies, and outcome measures, evidence was synthesized qualitatively rather than pooled quantitatively.

Results

Observational and secondary analyses evaluating finasteride 1 mg demonstrate consistent biologic activity on prostate-related pathways, most notably suppression of serum PSA (12). Prostate volume, LUTS, and progression-related outcomes were not predefined primary endpoints in available studies evaluating finasteride 1 mg, and direct clinical evidence demonstrating benefit for these outcomes at the 1 mg dose is lacking.

The available evidence is derived from heterogeneous cohorts with variation in age, baseline prostate characteristics, study design, and duration of follow-up, which limits direct comparability and precludes pooled quantitative analysis.

Discussion

The data above suggest that, although less potent than the standard 5 mg dose (4,6), the 1 mg formulation may exert biologically relevant effects on prostate-related parameters, based primarily on observational analyses rather than prospective trials with predefined urologic endpoints.

Observational studies have reported associations between long-term exposure to finasteride 1 mg and changes in prostate biologic activity (e.g., PSA suppression); however, these findings should be interpreted cautiously, as prostate volume, LUTS, and BPH progression events were not primary endpoints and study designs were heterogeneous (12). Given that prostate growth is gradual over time, even partial modulation of androgenic activity may have biological relevance. Given that prostate growth averages 0.6–1.0 mL/year in untreated men over age 40 years (1), even partial suppression can meaningfully delay the threshold at which LUTS become clinically significant or surgical intervention is required. The observed decreases in AUR and surgical risk at 5 mg further support disease-modifying effects in BPH (6,7,14), but causal inference at 1 mg cannot be established from the existing data.

While International Prostate Symptom Score (IPSS) reductions at 5 mg are modest (4,7), they nonetheless meet thresholds for clinical relevance (1), particularly in men with mild-to-moderate baseline symptoms. For these individuals, early intervention may delay the need for α-blockers or higher-dose 5-α-reductase inhibitors (5-ARIs), suggesting a potential role in early-stage disease management, rather than established preventive therapy (1,2).

Safety and tolerability data specific to finasteride 1 mg in BPH-related outcomes are limited. Pharmacodynamic studies demonstrate dose-dependent suppression of serum and tissue DHT at finasteride doses as low as 0.2–1 mg, confirming biological activity at lower doses but without direct assessment of clinical adverse event rates (9,10). Long-term observational and registry-based analyses primarily evaluate biochemical markers and exposure patterns rather than predefined safety endpoints (12).

In May 2025, the European Medicines Agency (EMA) confirmed a causal association between finasteride exposure and suicidal ideation, with the strongest signal observed in younger men using the 1 mg formulation for androgenic alopecia (15). This regulatory determination necessitates heightened caution, patient counseling, and psychiatric monitoring when considering long-term finasteride use.

Distinct from this regulatory finding, post-finasteride syndrome—characterized by persistent sexual, neuropsychiatric, and physical symptoms after discontinuation—has been described in case series, observational studies, and patient-reported outcomes. However, recent systematic reviews and expert commentaries emphasize that the condition remains controversial, with causality unproven and substantial methodological limitations, including reliance on retrospective designs, self-selection bias, and absence of large prospective epidemiologic studies (16-18). Clinicians should counsel patients regarding reported persistent symptoms, acknowledge the ongoing scientific debate, and monitor for mood or sexual changes during and after treatment.

The theoretical use of 1 mg finasteride as a preventative or early therapeutic strategy for BPH is particularly appealing for younger men with a strong family history of BPH (1,2), those with early prostate enlargement (volumes 25–30 mL) (1), or those with mild LUTS not yet warranting full-dose pharmacotherapy (1). The dual benefit of treating androgenic alopecia while also slowing prostate growth may improve adherence and broaden acceptance of therapy among this population (8).

Importantly, the available evidence does not support routine preventive use of finasteride 1 mg for BPH outside of clinical trials. The current body of evidence is limited by the predominance of observational and registry studies (12). RCTs directly assessing 1 mg finasteride in men at risk for or with early BPH are lacking (12). Furthermore, long-term outcomes beyond 10 years remain insufficiently studied, and it is unclear whether 1 mg can sustain protection into advanced age without eventual escalation to 5 mg (7,12).

Large-scale RCTs comparing 1 vs. 5 mg finasteride in men with baseline prostate volumes <30 mL are warranted (7). Biomarker-driven stratification, such as PSA kinetics (12) or DHT suppression levels (9,10), may help identify optimal candidates. Additional research should clarify whether a stepwise approach—initiating therapy at 1 mg and escalating to 5 mg when symptoms or prostate growth progress—maximizes both efficacy and tolerability (1,7). Regulatory data also provide an important foundation for understanding dose-response effects and pharmacokinetics (13).

When integrated with the robust evidence base of 5 mg therapy (4,6,7), the data suggest a dose-response continuum, where 1 mg confers biologic effects. The clinical evidence supporting finasteride 5 mg in BPH—including reductions in prostate volume, LUTS progression, acute urinary retention, and need for surgery—is summarized in Table 2. In clinical practice, this may translate to earlier initiation of therapy at 1 mg, followed by escalation to 5 mg as patients age and disease advances (1), thereby providing both preventative and therapeutic benefits across the disease course; however, whether 1 mg yields clinically meaningful BPH benefits remains unproven.

Finasteride suppresses serum PSA by approximately 40–50% after 6–12 months, even at 1 mg daily (8,12). As such, primary care physicians and urologists should be informed when a patient is taking finasteride so that PSA values are interpreted correctly—often approximated by doubling the PSA after sustained therapy for cancer screening purposes. Failure to account for this pharmacologic effect may underestimate prostate cancer risk or delay appropriate diagnostic evaluation.

Conclusions

Finasteride 1 mg daily, while originally developed for androgenic alopecia, produces measurable biologic effects on prostate-related pathways, including suppression of serum PSA and DHT (8-10,12). However, reductions in prostate volume, improvements in LUTS, and decreased risks of AUR or surgical intervention are supported only by RCTs evaluating finasteride 5 mg in men with BPH (4-7,14).

The available evidence for finasteride 1 mg should therefore be interpreted as biologic and hypothesis-generating rather than disease-modifying. In selected younger men or those with early prostate enlargement, a low-dose, stepwise approach may be conceptually appealing, but routine preventive use cannot be recommended outside of clinical trials. Safety considerations, including emerging psychiatric concerns, should be incorporated into patient counseling, and PSA values should be interpreted with appropriate adjustment in patients receiving finasteride (8,12,15). Prospective RCTs are required to confirm long-term outcomes, refine patient selection, and determine whether early low-dose therapy can meaningfully alter the natural history of BPH (1,2,7,13).

Acknowledgments

None.

Footnote

Reporting Checklist: The authors have completed the Narrative Review reporting checklist. Available at https://tau.amegroups.com/article/view/10.21037/tau-2025-aw-841/rc

Peer Review File: Available at https://tau.amegroups.com/article/view/10.21037/tau-2025-aw-841/prf

Funding: None.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-2025-aw-841/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. American Urological Association. Benign Prostatic Hyperplasia (BPH) Guideline. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline. 2021; amended 2023. Available online: https://www.auanet.org/guidelines-and-quality/guidelines/benign-prostatic-hyperplasia-(bph)-guideline
2. European Association of Urology. Management of Non-Neurogenic Male LUTS. Available online: https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts
3. Rittmaster RS. Finasteride. N Engl J Med 1994;330:120-5. [Crossref] [PubMed]
4. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992;327:1185-91. [Crossref] [PubMed]
5. Stoner EThe Finasteride Study Group. The clinical effects of a 5α-reductase inhibitor, finasteride, in BPH. J Urol 1992;147:1295-301. [Crossref] [PubMed]
6. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998;338:557-63. [Crossref] [PubMed]
7. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98. [Crossref] [PubMed]
8. D’Amico AV, Roehrborn CG. Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol 2007;8:21-5. [Crossref] [PubMed]
9. Drake L, Hordinsky M, Fiedler V, et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol 1999;41:550-4.
10. Dallob AL, Sadick NS, Unger W, et al. The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab 1994;79:703-6. [Crossref] [PubMed]
11. Zito PM, Bistas KG, Patel P, et al. Finasteride. In: StatPearls. Treasure Island: StatPearls Publishing; 2024.
12. Etzioni RD, Howlader N, Shaw PA, et al. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol 2005;174:877-81. [Crossref] [PubMed]
13. U.S. Food and Drug Administration. 20788 Propecia Tablets, 1mg Pharmacology Review. 1997. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20788_PROPECIA%20TABLETS,%201MG_PHARMR.PDF
14. Andersen JT, Nickel JC, Marshall VR, et al. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 1997;49:839-45. [Crossref] [PubMed]
15. Reuters. EU drugs regulator confirms suicidal thoughts as side effect of hair loss drug. 2025. Available online: https://www.reuters.com/business/healthcare-pharmaceuticals/eu-drugs-regulator-confirms-suicidal-thoughts-side-effect-anti-hair-loss-drug-2025-05-08/
16. Traish AM. Post-finasteride syndrome: a surmountable challenge for clinicians. Fertil Steril 2020;113:21-50. [Crossref] [PubMed]
17. Diviccaro S, Melcangi RC, Giatti S. Post-finasteride syndrome: An emerging clinical problem. Neurobiol Stress 2020;12:100209. [Crossref] [PubMed]
18. Cilio S, Tsampoukas G, Morgado A, et al. Post-finasteride syndrome - a true clinical entity? Int J Impot Res 2025;37:426-35. [Crossref] [PubMed]